Talking Back to Prozac

What Doctors Aren't Telling You About Prozac and the Newer Antidepressants

Peter R. Breggin, Ginger Ross Breggin

• Publisher: Open Road Media
• Year: 2014
• Print ISBN: 9781497638778
• eBook ISBN: 9781497617483
• Topic: Psychology
• Subtopic: Pharmacology
• Index: Psychology

A psychiatrist takes a critical look at this SSRI and newer medications that are among the most frequently prescribed drugs in America.
Prozac. Millions of Americans are on it. And just about everyone else is wondering if they should be on it, too. The claims of the pro?Prozac chorus are enticing: that it can cure everything from depression (the only disorder for which Prozac was originally approved) to fear of public speaking, PMS, obesity, shyness, migraine, and back pain—with few or no side effects. But is the reality quite different? At what price do we buy Prozac?induced euphoria and a shiny new personality?
Psychiatrist Peter Breggin, MD, and coauthor Ginger Ross Breggin answer these and other crucial questions in  Talking Back to Prozac. They explain what Prozac is and how it works, and they take a hard look at the real story behind today's most controversial drug:

• The fact that Prozac was tested in trials of four to six weeks in length before receiving FDA approval
• The difficulty Prozac's manufacturer had in proving its effectiveness during these tests
• The information on side effects that the FDA failed to include in its final labeling requirements
• How Prozac acts as a stimulant not unlike the addictive drugs cocaine and amphetamine
• The dangers of possible Prozac addiction and abuse
• The seriousness and frequency of Prozac's side effects, including agitation, insomnia, nausea, diarrhea, loss of libido, and difficulty reaching orgasm
• The growing evidence that Prozac can cause violence and suicide
• The social and workplace implications of using the drug not to cure depression but to change personality and enhance performance 

Using dramatic case histories as well as scientific research and carefully documented evidence, the Breggins expose the potentially damaging effects of Prozac. They also describe the resounding success that has been achieved with more humane alternatives for the treatment of depression.
Talking Back to Prozac provides essential information for anyone who takes Prozac or is considering taking it, and for those who prescribe it.

Bibliography

5-HT blockers and all that. (1990). The Lancet, 336, 345–346.

Baker, B. (1995, March). Though data lacking, antidepressants used widely in children. Clinical Psychiatry News, p. 16.

Abrams, Richard (1988). Electroconvulsive Therapy. New York: Oxford University Press.

Achenbach, Joel (1992, May 6). “Mind Over Gray Matter? Psychiatrists Debate Power of the Pill.” Washington Post, p. B1.

ACNP releases final task force report on antidepressant suicidality among adolescents. (2006). Psychiatric Services, 57, 283.

Ahtee, L., and K. Eriksson (1972). “5-Hydroxytryptamine and 5-Hydroxindo-lylacetic Acid Content in Brain of Rat Strains Selected for Their Alcohol Intake.” Physiology and Behavior, 8:123–126.

American Medical Association (1966). “Report of the Committee on Alcoholism and Addiction and Council on Mental Health.” Journal of the American Medical Association, 197:193–197.

American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.

American Psychiatric Association (1980). Tardive Dyskinesia: Report of the American Psychiatric Association Task Force on Late Neurological Effects of Antipsychotic Drugs. Washington, D.C.: American Psychiatric Association.

American Psychiatric Association (1987). Diagnostic and Statistical Manual of Mental Disorders (Third Edition, Revised) (DSM-III-R). Washington, D.C.: American Psychiatric Association.

American Psychiatric Association (1989). Treatments of Psychiatric Disorders. Washington, D.C.: American Psychiatric Association.

American Psychiatric Association (1992). Tardive Dyskinesia: A Task Force Report. Washington, D.C.: American Psychiatric Association.

Angier, Natalie (1990, August 16). “Eli Lilly Facing Million-Dollar Suits on Its Antidepressant Drug Prozac.” New York Times, p. 399.

Angier, Natalie (1991, February 7). “Suicidal Behavior Tied Again to Drug.” New York Times, p. B15.

Antonuccio, David (1993, August 23). “Psychotherapy vs. Medication for Depression: Challenging the Conventional Wisdom.” Presented at the Annual Convention of the American Psychological Association, Toronto, Canada.

Apter, Alan, Serena-Lynn Brown, Martin L. Korn, and Herman M. van Praag (1986). “Serotonergic Parameters of Aggression and Suicide.” In Mann, J. John, and Michael Stanley (eds.): Psychobiology of Suicidal Behavior. New York: New York Academy of Sciences, Chapter 12, pp. 284–301.

Armstrong, Louise (1993). And They Call It Help: The Psychiatric Policing of America’s Children. New York: Addison-Wesley Publishing Co.

Arno, Peter S., and Karyn L. Feiden (1992). Against the Odds: The Story of the AIDS Drug Development, Politics & Profits. New York: HarperCollins.

Associated Press (1990, August 8). “3rd Suit Against Lilly Antidepressant Drug.” Chicago Tribune.

Associated Press (1991, January 30). “Shannon Widow Sues Drug Company.” Variety.

Associated Press Release, San Francisco (1991, November 8). “Daughter Arrested in ‘Cannibal’ Attack.”

Associated Press (1992, February 13). “FDA Strips Breast Implant Critic of His Role.” Washington Post, p. A24.

Associated Press (1992, October 12). “White House Plan Bodes III for Drug Safety, Report Says.” Fort Wayne Journal-Gazette, p. 6A.

Avery, David, and George Winokur (1978, June). “Suicide, Attempted Suicide, and Relapse Rates in Depression.” Archives of General Psychiatry 35:749–753.

Avorn, Jerry, Milton Chen, and Robert Hartley (1982, July). “Scientific versus Commercial Sources of Influence on the Prescribing Behavior of Physicians.” American Journal of Medicine 73:5–28.

Baghurst, Peter A., Anthony J. McMichael, Neil R. Wiggs, Graham V. Vim-pani, Evelyn F. Robertson, Russell J. Roberts, and Shi-Lu Tong (1992, October 29). “Environmental Exposure to Lead and Children’s Intelligence at the Age of Seven Years.” New England Journal of Medicine 327:1279–1284.

Baird, R. E. (1991, December 13). “Embattled Drug at Issue in Death.” Colorado Daily (University of Colorado).

Baker, Barbara (1993, July). “Limited Data Suggest Fluoxetine Safe for Children.” Clinical Psychiatry News, p. 18.

Baldessarini, Ross J., and Elda Marsh (1990, February). “Fluoxetine and Side Effects.” Archives of General Psychiatry 47:191–192.

Baiter, M. B., and J. Levin (1969). “The Nature and Extent of Psychotropic Drug Usage in the United States.” Psychopharmacology Bulletin 5:3.

Bargmann, Eve, Sidney M. Wolfe, Joan Levin and the Public Citizen Health Research Group (1983). Stopping Valium. New York: Warner Books.

Barinaga, Marcia (1994, March 4). “How the Brain Weeds Its Garden.” Science 263:1225.

Baron, Bruce M., Ann-Marie Odgen, Barry W. Siegel, James Stegeman, Richard C. Ursillo, and Mark W. Dudley (1988). “Rapid Down Regulation of B [editor, beta]-adrenoreceptors by Coadministration of Desipra-mine and Fluoxetine.” European Journal of Pharmacology 154:125–134.

Belles, Christopher (1993, November 8). “Happiness in a Pill.” The Eagle (American University, Washington, D.C.), p. B1.

Belli, Anne (1991, June 23). “Family Takes on Drug Firm: Prozac Blamed in Man’s Suicide.” The Dallas Morning News.

Bergstromm, Richard F., Albert L. Peyton, and Louis Lemberger (1992).

“Quantification and Mechanism of Fluoxetine and Tricyclic Antidepressant Interaction.” Clinical Pharmacology and Therapeutics 51:239–248.

Berry, Wendell (1977). The Unsettling of America; Culture & Agriculture. San Francisco: Sierra Club Books.

Blier, Pierre, and Claude de Montigny (1983, June). “Electrophysiological Investigations on the Effect of Repeated Zimelidine Administration on Serotonergic Neurotransmission in the Rat.” Journal of Neuroscience 3:1270–1278.

Blier, Pierre, Yves Chaput, and Claude de Montigny (1988). “Long-term 5-HT Reuptake Blockade, But No Monoamine Oxidase Inhibition, Decreases the Function of Terminal 5-HT Autoreceptors; an Electrophysiological Study of the Rat Brain.” Naunyn-Schmiederberg’s Archives of Pharmacology 337:246–254.

Blodgett, Nancy (1990, November). “Eli Lilly Drug Targeted.” ABA Journal, p. 28.

Bost, Robert O., and Philip M. Kemp (1992, March/April). “A Possible Association Between Fluoxetine Use and Suicide. “Journal of Analytical Toxicology 16:142–145.

Boulos, C, S. Kutcher, D. Gardner, and E. Young (1992). “An Open Naturalistic Trial of Fluoxetine in Adolescents and Young Adults with Treatment-Resistant Major Depression.” Journal of Child and Adolescent Psychophar-macology 2:103–111.

Bower, Bruce (1992, October 10). “Efficacy of Antidepressants Challenged.” Science 142:231.

Boyer, W. E, and J. P. Feighner (1992, February). “An Overview of Paroxetine.” Journal of Clinical Psychiatry 53 Supplement, pp. 3–6.

Brandes, Lome J., Randi J. Arron, R. Patricia Bogdanovic, Jiangang Tong, Cheryl L. F. Zaborniak, Georgina R. Hogg, Robert C. Warrington, Wei Fang, and Frank S. LaBella (1992, July 1). “Stimulation of Malignant Growth in Rodents by Antidepressant Drugs at Clinically Relevant Doses.” Cancer Research 52:3796–3800.

Brandt, Aviva L. (1994, March 3). “Doctor Advises Reporter to Check Out Prozac.” Associated Press wire service.

Brandt, Aviva L. (1994, March 4). “‘Piper’ Suggests Side Dish at Meal with Writer: Prozac.” The Arizona Republic, p. 1.

Brataas, Anne (1991, March 10). “Light in the Darkness.” St. Paul Pioneer Press, p. 1F.

Breggin, Ginger, and Peter Breggin (1992, spring). “Feminist Paradigms and Conflict Resolution.” ICAR Newsletter (Institute for Conflict Analysis and Resolution, George Mason University), p. 1.

Breggin, P. (1991c). Toxic psychiatry: Why therapy, empathy and love must replace the drugs, electroshock and biochemical theories of the “new psychiatry.” New York: St. Martin’s.

Breggin, P. (1992b). A case of fluoxetine-induced stimulant side effects with suicidal ideation associated with a possible withdrawal syndrome (“crashing”). International Journal of Risk and Safety in Medicine, 3, 325–328.

Breggin, P. (1997a). Brain-disabling treatments in psychiatry. New York: Springer.

Breggin, P. (1997b). The heart of being helpful. New York: Springer.

Breggin, P. (2001a). The Antidepressant Fact Book. Cambridge, MA: Perseus Books.

Breggin, P., & Breggin, G. (1994a). Talking back to Prozac: What doctors aren’t telling you about today’s most controversial drug. New York: St. Martin’s.

Breggin, P. (2003). Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis. Ethical Human Sciences and Services, 5, 225–246.

Breggin, P. (2006a). Court filing makes public my previously suppressed analysis of Paxil’s effects. Ethical Human Psychology and Psychiatry, 8, 77–84.

Breggin, P. (2006b). Drug company suppressed data on paroxetine-induced stimulation: Implications for violence and suicide. Ethical Human Psychology and Psychiatry, 8, 255–263.

Breggin, P. (2006c). How GlaxoSmithKline suppressed data on Paxil-induced akathisia: Implications for suicide and violence. Ethical Human Psychology and Psychiatry, 8, 91–100.

Breggin, P. (2008a). Brain-disabling treatments in psychiatry: Drugs, electroshock and the psychopharmaceutical complex. New York: Springer Publishing Company.

Breggin, P. (2008b). Medication madness: a psychiatrist exposes the dangers of mood-altering medications. New York: St. Martin’s Press.

Breggin, Peter (1971). The Crazy from the Sane (a novel). New York: Lyle Stuart.

Breggin, Peter (1979). Electroshock: Its Brain-Disabling Effects. New York: Springer Publishing Company.

Breggin, Peter (1980). “Brain-Disabling Therapies.” In Valenstein, E. (ed.): The Psychosurgery Debate. San Fr...

Table of contents

• Cover
• Acknowledgments
• Acronyms of Organizations
• How to Use This Book
• Introduction
• One - Should We Listen to Prozac?
• Two - A Primer on How Prozac Is Supposed to Work
• Three - The Real Story Behind Prozac’s Approval by the FDA
• Four - The Real Story Behind Prozac’s Side Effects
• Five - Drug Addiction and Abuse A Comparison Between Prozac and Amphetamines
• Six - Drug-Induced Paranoid, Violence, Depression, and Suicide: A Comparison Between Prozac and Amphetamines
• Seven - Can Prozac Cause Violence and Suicide? What Survivors, Independent Researchers, and the FDA Have to Say
• Eight - Pushing Drugs in America: The Long Financial Tentacles of Eli Lilly
• Nine - How and Why to Stop Taking Psychiatric Drugs
• Ten - Understanding and Overcoming Depression
• How to File an Adverse Drug Reaction Report with the FDA
• Notes
• Bibliography
• About the Authors
• Endnotes
• Copyright